Professor Thomas Powles

MBBS, MRCP, MD
Professor of Genitourinary Oncology; Director, Barts Cancer Centre at St. Bartholomew's Hospital; Lead for Solid Tumour Research
Group Leader
Research Focus

My main research interests are in genital and urinary cancers, and I lead a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.

Key Publications

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med (2019) 380(12):1116-1127. PMID: 30779529

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet (2019) 393(10189):2404-2415. PMID: 31079938

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature (2018) 554(7693):544-548. PMID: 29443960

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med (2018) 24(6):749-757. PMID: 29867230

Major Funding
  • 2015-2020- Astrazeneca UK Limited, PDL-1 combination targeted therapy with AZ6094 in metastatic renal cancer (CALYPSO)
  • 2015-2020- F Hoffmann-La Roche Ltd, Treatment of transitional cell carcinoma of the bladder-ABACUS

Other Activities
  • NCRN bladder cancer CSG
  • NCRN renal cancer CSG
  • NCRN translational oncology group
  • NCRN CRPC studies group
Research

I am the lead for solid tumor research at Barts Cancer Institute. I also lead the genitourinary (GU) cancer group at BCI.

My work focuses on a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies. They exploit functional imaging and tissue collection.

Alongside these trials, our research focuses on correlation of novel biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to therapy.

I have written over 100 peer review papers in this area and have grant income from national and international funding bodies.

I am on the editorial board of a number of journals and am part of the faculty for the major global oncology meetings.

Other Activities
  • NCRN bladder cancer CSG
  • NCRN renal cancer CSG
  • NCRN translational oncology group
  • NCRN CRPC studies group
  • EORTC-GU executive committee
  • ESMO faculty for GU cancer
  • Editorial board of Clinical Genitourinary Cancer
  • Co chair of trans Atlantic bladder cancer consortium
  • International guidelines for testis cancer and renal cancer
Major Funding
  • 2015-2020- Astrazeneca UK Limited, PDL-1 combination targeted therapy with AZ6094 in metastatic renal cancer (CALYPSO)
  • 2015-2020- F Hoffmann-La Roche Ltd, Treatment of transitional cell carcinoma of the bladder-ABACUS
  • 2013-2018- Millenium Pharmaceuticals Inc, NEPTUNE study of neoadjuvant TAK-700 and leuprorelin acetate versus surgery alone in intermediate and high risk clinically localized
  • 2012-2017- AstraZeneca UK Limited, Comparing AZD2014 and EVEROLIMUS
  • 2010-2015- GlaxoSmithKline Research & Development, A phase II study investigating upfront pazopanib in metastatic clear cell renal cancer (PANTHER)
Recent Publications

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Powles T, Bellmunt J, Comperat E et al. Annals of Oncology (2022) 33(7) 244-258

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial Albiges L, Tannir NM, Burotto M et al. European Urology (2022) 81(7) 266-271

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit Choueiri TK, Albiges L, Atkins MB et al. Clinical Cancer Research (2022) 28(7) 831-839

Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis Martini A, Raggi D, Fallara G et al. Cancer Treatment Reviews (2022) 104(7)

Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma Sonpavde GP, Sternberg CN, Loriot Y et al. European Journal of Cancer (2022) 163(7) 55-65

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial. Powles T, Park SH, Voog E et al. Journal of Clinical Oncology (2022) 40(10) 487-487

Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. Powles T, Choueiri TK, Burotto M et al. Journal of Clinical Oncology (2022) 40(10) 350-350

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. Choueiri TK, Tomczak P, Park SH et al. Journal of Clinical Oncology (2022) 40(10) 290-290

The effect of anti-cancer therapy on immunological response to COVID-19 vaccination. Jackson-Spence F, Toms C, Yang Y-H et al. Journal of Clinical Oncology (2022) 40(10) 319-319

2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma Bedke J, Albiges L, Capitanio U et al. European Urology (2022) 81(7) 134-137

For additional publications, please click here
Biography

I qualified from St Bartholomew’s Medical School in 1996 and trained in medical oncology at Imperial College. I completed post-graduate training in oncology in 2005 and received an MD from the University of London in 2006. My thesis was in mechanisms of resistance to therapy in urology cancers.